Advertisement

Topics

Chiesi Farmaceutici S.p.A. Company Profile

08:53 EDT 19th June 2018 | BioPortfolio

Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3 manufacturing plants and 4 research centres situated in Parma (Italy), Paris, Rockville (Maryland - USA) and Chippenham (UK). The Company's history of continual development is founded on concepts which constitute the basis for its management: strategic innovation, internationalization and ability to plan taking care in the creation of socially compatible economic values.

 

Thanks to the process of internationalization and strategic alliances with international pharmaceutical groups, Chiesi Group drugs and technologies are today distributed in over 65 countries. The Group employs over 3,800 people, approximately 320 of whom are researchers who work in the four Research and Development laboratories, and approximately 600 of whom are employed in the manufacturing sites in Italy, France and Brazil.

Our Mission

 

  • Our aim is to be recognised as a research-focused international Group, able to develop and commercialise innovative pharmaceutical solutions to improve the quality of human life.
  • We want to maintain a high quality entrepreneurial team characterised by self confidence and a collaborative spirit.
  • Our goal is to combine commitment to results with integrity, operating in a socially and environmentally responsible manner

Location

Via Palermo, 26/A
Parma
IT-43122
Italy

Contact

Phone: +39 0521 279
Fax: +39 0521 774468


News Articles [45 Associated News Articles listed on BioPortfolio]

MA granted for drug tested in just 34 patients

An absence of comprehensive data did not prevent Italian family-owned drugmaker Chiesi Farmaceutici from…

Pending EC decision: CHF 5993 Chiesi Farmaceutici S.p.A., beclometasone dipropionate anhydrous / formoterol fumarate dihydrate / glycopyrronium, Opinion date: 22-Feb-2018

Human medicines European public assessment report (EPAR): Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.), beclometasone / formoterol / glycopyrronium bromide, Revision: 0, Authorised

EU Panel Backs Two Triple Combo Drugs for COPD Maintenance

CHF 5993 and Trydonis, from Chiesi Farmaceutici SpA, combine a glucocorticoid, a long-acting beta-2 receptor agonist, and a long-acting muscarinic antagonist. International Approvals

NICE rejects Chiesi’s Lamzede

It is currently looking unlikely that Chiesi’s Lamzede will become routinely available on the NHS for patients with alpha-mannosidosis, after cost-regulators issued a preliminary rejection of th...

Chiesi's enzyme disorder therapy approved in EU

Chiesi's marketing application for Lamzede, or velmanase alfa, as long-term enzyme replacement therapy for the treatment of n -More- 

EU green light for Chiesi’s Lamzede

European regulators have green-lighted Chiesi’s Lamzede as the first long-term enzyme replacement therapy to treat non-neurological manifestations in patients with mild to moderate alpha-mannosi...

Chiesi, new partner in d·HEALTH Barcelona program

Chiesi, new partner in d·HEALTH Barcelona program28.05.2018

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Curosurf [Cornerstone Therapeutics Inc.]

CUROSURF (poractant alfa)Intratracheal Suspension

PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Triticum vulgare extract exerts an anti-inflammatory action in two in vitro models of inflammation in microglial cells.

Triticum vulgare has been extensively used in traditional medicine thanks to its properties of accelerating tissue repair. The specific extract of Triticum vulgare manufactured by Farmaceutici Damor (...

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma

The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combina...

Evaluation of the Filler Performance on the Nasolabial Folds of Aliaxin® EV With and Without Lidocaine 0.3%

Evaluation of the filler performance on the nasolabial folds of Aliaxin® EV with and without lidocaine 0.3%: comparison within subjects (half face method)

Evaluation of the Re-volumizing Performance of Aliaxin (New Trademark)

Aim of the study is to evaluate the re-volumizing performance and the duration effect of the product Aliaxin (new trademark) in women aged 40-65 years with midface volume defects due to ag...

Early Viscosupplementation After Partial Meniscectomy: a Randomized Controlled Trial

The rational of intra-articular viscosupplementation is based on both the biological and mechanical properties of HA, which exerts positive effects on the modulation of the entire joint en...

Companies [7 Associated Companies listed on BioPortfolio]

Chiesi Farmaceutici S.p.A.

Chiesi Pharmaceuticals, which started up in 1935 as a small family company is today an international company in the pharmaceutical sector and operates in all 5 continents with 24 direct branches, 3 ...

Chiesi Group

The Company, founded in Parma in 1935, is today an international reality in the pharmaceutical market. With global operations consisting of 21 direct affiliates, 3 manufacturing sites, and 3 research ...

Fidia Farmaceutici

Fidia Farmaceutici is part of Fidia Pharma Group, an Italian multinational company, with R&D, manufacturing and sales capabilities, and an extensive product portfolio mainly based...

Mediolanum farmaceutici S.p.A

Nil

Dompé Farmaceutici S.p.A.

Dompé is one of the most dynamic, flexible and innovative set-ups on the European scene.Successful in the traditional pharmaceutical market in the treatment of respiratory and osteoarticular patholog...

More Information about "Chiesi Farmaceutici S.p.A." on BioPortfolio

We have published hundreds of Chiesi Farmaceutici S.p.A. news stories on BioPortfolio along with dozens of Chiesi Farmaceutici S.p.A. Clinical Trials and PubMed Articles about Chiesi Farmaceutici S.p.A. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chiesi Farmaceutici S.p.A. Companies in our database. You can also find out about relevant Chiesi Farmaceutici S.p.A. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record